Similar articles for PMID: 33122347

Year	Number of Results
2001	2
2009	1
2011	1
2012	1
2013	1
2014	1
2015	2
2016	9
2017	8
2018	25
2019	42
2020	33
2021	10

1

Emicizumab-Induced Seronegative Full-House Lupus Nephritis in a Child.

Chehade H, Cachat F, Beck-Popovic M, Rotman S, Diezi L, Albisetti M, Alberio L, Young G, Rizzi M. Chehade H, et al. Pediatrics. 2020 Nov;146(5):e20200123. doi: 10.1542/peds.2020-0123. Pediatrics. 2020. PMID: 33122347

2

Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.

Nogami K, Soeda T, Matsumoto T, Kawabe Y, Kitazawa T, Shima M. Nogami K, et al. J Thromb Haemost. 2018 Jul;16(7):1383-1390. doi: 10.1111/jth.14135. Epub 2018 May 27. J Thromb Haemost. 2018. PMID: 29734520 Free article.

3

Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.

Nogami K, Matsumoto T, Tabuchi Y, Soeda T, Arai N, Kitazawa T, Shima M. Nogami K, et al. J Thromb Haemost. 2018 Jun;16(6):1078-1088. doi: 10.1111/jth.14022. Epub 2018 May 13. J Thromb Haemost. 2018. PMID: 29645406 Free article.

4

Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.

Patel AM, Corman SL, Chaplin S, Raimundo K, Sidonio RF. Patel AM, et al. J Med Econ. 2019 Dec;22(12):1328-1337. doi: 10.1080/13696998.2019.1669614. Epub 2019 Oct 7. J Med Econ. 2019. PMID: 31530050

5

Emicizumab for hemophilia A with factor VIII inhibitors.

Young G, Callaghan M, Dunn A, Kruse-Jarres R, Pipe S. Young G, et al. Expert Rev Hematol. 2018 Nov;11(11):835-846. doi: 10.1080/17474086.2018.1531701. Epub 2018 Oct 10. Expert Rev Hematol. 2018. PMID: 30278802 Review.

6

Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A.

Díaz-Ricart M, Isola IM, Escolar G. Díaz-Ricart M, et al. Drugs Today (Barc). 2018 Oct;54(10):591-600. doi: 10.1358/dot.2018.54.10.2869771. Drugs Today (Barc). 2018. PMID: 30398480 Review.

7

Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A.

Müller J, Pekrul I, Pötzsch B, Berning B, Oldenburg J, Spannagl M. Müller J, et al. Thromb Haemost. 2019 Sep;119(9):1384-1393. doi: 10.1055/s-0039-1692427. Epub 2019 Jun 16. Thromb Haemost. 2019. PMID: 31203578 Free article. Review.

8

Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab.

Yada K, Nogami K. Yada K, et al. Arterioscler Thromb Vasc Biol. 2020 May;40(5):1148-1154. doi: 10.1161/ATVBAHA.120.312919. Epub 2020 Apr 2. Arterioscler Thromb Vasc Biol. 2020. PMID: 32237902 Review.

9

Evaluating the safety of emicizumab in patients with hemophilia A.

Langer AL, Etra A, Aledort L. Langer AL, et al. Expert Opin Drug Saf. 2018 Dec;17(12):1233-1237. doi: 10.1080/14740338.2019.1551356. Epub 2018 Nov 28. Expert Opin Drug Saf. 2018. PMID: 30462521 Review.

10

Emicizumab for hemophilia A without inhibitors.

Cafuir L, Kruse-Jarres R, Mancuso ME, Kempton CL. Cafuir L, et al. Expert Rev Hematol. 2019 Jul;12(7):515-524. doi: 10.1080/17474086.2019.1624519. Epub 2019 Jun 4. Expert Rev Hematol. 2019. PMID: 31130012 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed